|
1
|
Takeuchi H, Fernández-Valdivia RC, Caswell
DS, Nita-Lazar A, Rana NA, Garner TP, et al: Rumi functions as both
a protein O-glucosyltransferase and a protein O-xylosyltransferase.
Proc Natl Acad Sci USA. 108:16600–16605. 2011.
|
|
2
|
Fernandez-Valdivia R, Takeuchi H,
Samarghandi A, Lopez M, Leonardi J, Haltiwanger RS and Jafar-Nejad
H: Regulation of mammalian Notch signaling and embryonic
development by the protein O-glucosyltransferase Rumi. Development.
138:1925–1934. 2011.
|
|
3
|
Sethi MK, Buettner FF, Ashikov A, Krylov
VB, Takeuchi H, Nifantiev NE, et al: Molecular cloning of a
xylosyltransferase that transfers the second xylose to
O-glucosylated epidermal growth factor repeats of notch. J Biol
Chem. 287:2739–2748. 2012.
|
|
4
|
Ma W, Du J, Chu Q, Wang Y, Liu L, Song M
and Wang W: hCLP46 regulates U937 cell proliferation via Notch
signaling pathway. Biochem Biophys Res Commun. 408:84–88. 2011.
|
|
5
|
Teng Y, Liu Q, Ma J, Liu F, Han Z, Wang Y
and Wang W: Cloning, expression and characterization of a novel
human CAP10-like gene hCLP46 from CD34(+) stem/progenitor cells.
Gene. 371:7–15. 2006.
|
|
6
|
Wang Y, Chang N, Zhang T, Liu H, Ma W, Chu
Q, et al: Overexpression of human CAP10-like protein 46 KD in
T-acute lymphoblastic leukemia and acute myelogenous leukemia.
Genet Test Mol Biomarkers. 14:127–133. 2010.
|
|
7
|
Pierelli L, Marone M, Bonanno G, Mozzetti
S, Rutella S, Morosetti R, et al: Modulation of bcl-2 and p27 in
human primitive proliferating hematopoietic progenitors by
autocrine TGF-beta1 is a cell cycle-independent effect and
influences their hematopoietic potential. Blood. 95:3001–3009.
2000.
|
|
8
|
Cipriano R, Kan CE, Graham J, Danielpour
D, Stampfer M and Jackson MW: TGF-beta signaling engages an
ATM-CHK2-p53-independent RAS-induced senescence and prevents
malignant transformation in human mammary epithelial cells. Proc
Natl Acad Sci USA. 108:8668–8673. 2001.
|
|
9
|
Bardeesy N, Morgan J, Sinha M, Signoretti
S, Srivastava S, Loda M, et al: Obligate roles for p16(Ink4a) and
p19(Arf)-p53 in the suppression of murine pancreatic neoplasia. Mol
Cell Biol. 22:635–643. 2002.
|
|
10
|
Liu P, Zhang C, Feng JB, Zhao YX, Wang XP,
Yang JM, et al: Cross talk among Smad, MAPK, and integrin signaling
pathways enhances adventitial fibroblast functions activated by
transforming growth factor-beta1 and inhibited by Gax. Arterioscler
Thromb Vasc Biol. 28:725–731. 2008.
|
|
11
|
Bran GM, Sommer UJ, Goessler UR, Hörmann
K, Riedel F and Sadick H: TGF-β1 antisense impacts the SMAD
signalling system in fibroblasts from keloid scars. Anticancer Res.
30:3459–3463. 2010.
|
|
12
|
Janknecht R, Wells NJ and Hunter T:
TGF-beta-stimulated cooperation of smad proteins with the
coactivators CBP/p300. Genes Dev. 12:2114–2119. 1998.
|
|
13
|
Kim RH, Wang D, Tsang M, Martin J, Huff C,
de Caestecker MP, et al: A novel smad nuclear interacting protein,
SNIP1, suppresses p300-dependent TGF-beta signal transduction.
Genes Dev. 14:1605–1616. 2000.
|
|
14
|
Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y
and Wang XF: Transforming growth factor beta induces the
cyclin-dependent kinase inhibitor p21 through a p53-independent
mechanism. Proc Natl Acad Sci USA. 92:5545–5549. 1995.
|
|
15
|
McConnell BB, Gregory FJ, Stott FJ, Hara E
and Peters G: Induced-expression of p16(INK4a) inhibits both CDK4-
and CDK2-associated kinase activity by reassortment of
cyclin-CDK-inhibitor complexes. Mol Cell Biol. 19:1981–1989.
1999.
|
|
16
|
Aprelikova O, Xiong Y and Liu ET: Both p16
and p21 families of cyclin-dependent kinase (CDK) inhibitors block
the phosphorylation of cyclin-dependent kinases by the
CDK-activating kinase. J Biol Chem. 270:18195–18197. 1995.
|
|
17
|
Bockstaele L, Kooken H, Libert F, Paternot
S, Dumont JE, de Launoit Y, et al: Regulated activating Thr172
phosphorylation of cyclin-dependent kinase 4(CDK4): its
relationship with cyclins and CDK ‘inhibitors’. Mol Cell Biol.
26:5070–5085. 2006.
|
|
18
|
Noh SJ, Li Y, Xiong Y and Guan KL:
Identification of functional elements of p18INK4C essential for
binding and inhibition of cyclin-dependent kinase (CDK) 4 and CDK6.
Cancer Res. 59:558–564. 1999.
|
|
19
|
Omura-Minamisawa M, Diccianni MB, Chang
RC, Batova A, Bridgeman LJ, Schiff J, et al: p16/p14(ARF) cell
cycle regulatory pathways in primary neuroblastoma: p16 expression
is associated with advanced stage disease. Clin Cancer Res.
7:3481–3490. 2001.
|
|
20
|
Yao J, Pollock RE, Lang A, Tan M, Pisters
PW, Goodrich D, et al: Infrequent mutation of the p16/MTS1 gene and
overexpression of cyclin-dependent kinase 4 in human primary
soft-tissue sarcoma. Clin Cancer Res. 4:1065–1070. 1998.
|
|
21
|
Kubo A, Nakagawa K, Varma RK, Conrad NK,
Cheng JQ, Lee WC, et al: The p16 status of tumor cell lines
identifies small molecule inhibitors specific for cyclin-dependent
kinase 4. Clin Cancer Res. 5:4279–4286. 1999.
|
|
22
|
Stein GH, Drullinger LF, Soulard A and
Dulić V: Differential roles for cyclin-dependent kinase inhibitors
p21 and p16 in the mechanisms of senescence and differentiation in
human fibroblasts. Mol Cell Biol. 19:2109–2117. 1999.
|
|
23
|
Akervall J, Bockmühl U, Petersen I, Yang
K, Carey TE and Kurnit DM: The gene ratios c-MYC:cyclin-dependent
kinase (CDK)N2A and CCND1:CDKN2A correlate with poor prognosis in
squamous cell carcinoma of the head and neck. Clin Cancer Res.
9:1750–1755. 2003.
|
|
24
|
Mihira H, Suzuki HI, Akatsu Y, Yoshimatsu
Y, Igarashi T, Miyazono K and Watabe T: TGF-β-induced mesenchymal
transition of MS-1 endothelial cells requires Smad-dependent
cooperative activation of Rho signals and MRTF-A. J Biochem.
151:145–156. 2012.
|
|
25
|
Zhang SJ, Endo S, Ichikawa T, Washiyama K
and Kumanishi T: Frequent deletion and 5′ CpG island methylation of
the p16 gene in primary malignant lymphoma of the brain. Cancer
Res. 58:1231–1237. 1998.
|
|
26
|
Alcorta DA, Xiong Y, Phelps D, Hannon G,
Beach D and Barrett JC: Involvement of the cyclin-dependent kinase
inhibitor p16 (INK4a) in replicative senescence of normal human
fibroblasts. Proc Natl Acad Sci USA. 93:13742–13747. 1996.
|
|
27
|
Dreyling MH, Bullinger L, Ott G,
Stilgenbauer S, Müller-Hermelink HK, Bentz M, et al: Alterations of
the Cyclin D1/p16-pRB Pathway in mantle cell lymphoma. Cancer Res.
57:4608–4614. 1997.
|
|
28
|
FitzGerald MG, Harkin DP, Silva-Arrieta S,
MacDonald DJ, Lucchina LC, Unsal H, et al: Prevalence of germ-line
mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis
of a clinic-based population. Proc Natl Acad Sci USA. 93:8541–8545.
1996.
|
|
29
|
Cai D, Byth KF and Shapiro GI: AZ703, an
imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and
2, induces E2F-1-dependent apoptosis enhanced by depletion of
cyclin-dependent kinase 9. Cancer Res. 66:435–444. 2006.
|
|
30
|
Park DS, Morris EJ, Bremner R, Keramaris
E, Padmanabhan J, Rosenbaum M, et al: Involvement of retinoblastoma
family members and E2F/DP complexes in the death of neurons evoked
by DNA damage. J Neurosci. 20:3104–3114. 2000.
|
|
31
|
Bartkova J, Lukas J, Guldberg P, Alsner J,
Kirkin AF, Zeuthen J and Bartek J: The p16-cyclin D/Cdk4-pRb
pathway as a functional unit frequently altered in melanoma
pathogenesis. Cancer Res. 56:5475–5483. 1996.
|
|
32
|
Tsukiyama-Kohara K, Toné S, Maruyama I,
Inoue K, Katsume A, Nuriya H, et al: Activation of the
CKI-CDK-Rb-E2F pathway in full genome hepatitis C virus-expressing
cells. J Biol Chem. 279:14531–14541. 2004.
|
|
33
|
Guo K and Walsh K: Inhibition of
myogenesis by multiple cyclin-Cdk complexes. Coordinate regulation
of myogenesis and cell cycle activity at the level of E2F. J Biol
Chem. 272:791–797. 1997.
|
|
34
|
Ojima H, Saito K, Yamauchi H, Yamaki E,
Idetu A, Hosouchi Y, Nishida Y, et al: P16 protein abnormality in
Epstein-Barr virus-associated gastric carcinomas. Anticancer Res.
26:933–937. 2006.
|
|
35
|
Alani RM, Young AZ and Shifflett CB: Id1
regulation of cellular senescence through transcriptional
repression of p16/Ink4a. Proc Natl Acad Sci USA. 98:7812–7816.
2001.
|
|
36
|
Yuen PW, Man M, Lam KY and Kwong YL:
Clinicopathological significance of p16 gene expression in the
surgical treatment of head and neck squamous cell carcinomas. J
Clin Pathol. 55:58–60. 2002.
|
|
37
|
Singh RP, Agarwal C and Agarwal R:
Inositol hexaphosphate inhibits growth, and induces G1 arrest and
apoptotic death of prostate carcinoma DU145 cells: modulation of
CDKI-CDK-cyclin and pRb-related protein-E2F complexes.
Carcinogenesis. 24:555–563. 2003.
|
